The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | Patient selection for selinexor
In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly comments on patient selection when considering selinexor for treating multiple myeloma (MM). Although some patients may experience the gastrointestinal (GI) side effects associated with this agent, Dr Zamagni does not think that any group of patients should be entirely excluded from receiving the drug as a result of this. Instead, patient selection should be guided by patient refractoriness to other approved therapies. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
